Disclosures. Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.

Size: px
Start display at page:

Download "Disclosures. Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes."

Transcription

1 1:05-2:20pm ADD & ADHD in Children and Adults: Beyond Stimulants SPEAKER Daniel Press, MD ADD & ADHD in Children and Adults: Beyond Stimulants Daniel Press, M.D. Associate Professor in Neurology Beth Israel Deaconess Medical Center and Harvard Medical School Disclosures No relationship to pharmaceutical industry I may be mentioning off-label use of medications

2 Definition of ADHD A developmental disorder that begins in childhood Impairments in attention, either with or without hyperactivity and impulsivity These impairments cause clear problems in functioning DSM 5 Criteria Persistent inattention +/ hyperactivity that interferes with function and is not solely oppositional, defiant, hostile or due to failure to understand. Symptoms begin before age of 12 Present in two or more settings with clear evidence of a significant problem No other disorder (depression, thought disorder) to explain symptoms

3 Adult ADHD Like pediatric ADHD, it must begin in childhood Symptoms continue past adolescence, with problems in organization, vigilance, and distractibility Generally, hyperactivity abates but impulsivity can remain a problem Between 10 50% of childhood ADHD continues into adulthood Patient SP in kindergarten Epidemiology 3 5% of children are diagnosed with ADHD, making it the most common LD In childhood, boys outnumber girls by 2:1 for inattentive type and 4:1 for hyperactive type. Girls with inattentive type may have fewer behavioral problems, leading to underdiagnosis The percentage of children who remain symptomatic into adulthood ranges from 4% to 80% depending on the criteria used for diagnosis ADHD Does Not Exist Cultural bias to explain poor performance (Lake Wobegon effect) ADHD claims to make a disorder out of a personality trait, it is normal variance Medicalizing our deficits e.g. social phobia, alopecia, short stature Vastly different incidences across cultures, states, and even zip codes

4 ADHD Does Not Exist Starting school early because of a person s birthday increases diagnosis Difference in rate of ADHD per 10,000 children Rate of ADHD diagnosis by month of birth Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Month of Birth Rate of ADHD diagnosis by month of birth States with Sept Cutoff States without Sept Cutoff ADHD Does Exist Difference in rate of ADHD per 10,000 children July vs Aug vs Sept vs July vs. Aug vs. Sept vs. Aug. Sept Oct Aug. Sept. Oct. Month of Birth Cultural demands do not negate a disorder (e.g. dyslexia) Normal variance can still cause disease (hypertension) Structural and functional imaging studies show differences in specific brain regions Family clustering suggests genetic role

5 SP Family Pedigree G. Bush et. al, Biol. Psychiatry 1999

6 Attentional Network Compromise position? DLPFC Lateral Surface Parietal Ant. Cingulate Medial Wall If attentional problems are symptomatic, and out of proportion to a personʼs intelligence, then it is at least reasonable to consider treatment. VLPFC Cereb ellum G. Bush Biol Psych 2011 Causes of ADHD Genes Heritability of % of phenotypic variance But known genes account for only 3% Unknown genes, genes with small effects, genegene interactions* Environment Mother who smoke during pregnancy 2x risk Patients with obesity and diabetes Maternal DM during pregnancy *Zuk O, PNAS 2012 Froehlich TE Pediatrics 2009 Differential Diagnosis Obstructive Sleep Apnea (ask about snoring, daytime sleepiness, naps, etc) Mood disorders both depression and hypomania can impair attention Previous closed head injury, focal lesions, toxic metabolic encephalopathies Seizure disorders (staring spells) Physical or sexual abuse

7 Differentiating ADD from Bipolar disorder ADHD Bipolar Time course Constant Episodic Sleep patterns Normal Markedly shortened Impulsivity Moderate Severe Comorbid Psychiatric Conditions Up to 75% of adult patients with ADHD have a comorbid psychiatric illness Other learning disorders (e.g. dyslexia) Mood disorders (Odds ratio 2.7 to 7.5) Substance Abuse (OR 1.5 to 7.9) Intermittent Explosive Disorder (OR 3.7) Kessler et. al, Am J Psych 2006 Overlapping conditions Comorbid Conditions: Treatment Implications Anxiety + Depression Attention Deficit Disorder Oppositional Behavior + Conduct Disorder Depression: Approximately 15 30% of patients who present with ADHD have comorbid depression Activating antidepressants can help both conditions: Bupropion (wellbutrin) Atomoxetine (strattera) Venlafaxine (effexor) Internalizing Disorders Externalizing Disorders Feldman and Reiff NEJM 2014

8 Comorbid Conditions: Treatment Implications II Bipolar Disorder Stimulants can precipitate mania. Either use a concomitant mood stabilizing medication or use an activating antidepressant medication (bupropion). Substance Abuse 25 45% comorbidity, especially with anti social personality. Early treatment may prevent substance abuse. Once present, avoid stimulants. Comorbid Conditions: Treatment Implications III Comorbid learning disabilities 20 30% of children with ADHD have reading problems (dyslexia) or arithmetic problems. Reading skills improve with stimulant medication in ADHD + dyslexia children, but not children with dyslexia alone. Tests of Attention MoCA Test Vigilance/Sustained Attention Continuous Performance Tasks Divided Attention Trails B, Stroop Color Interference Working Memory Digit Span Backwards, Verbal Fluency Response Inhibition Motor Go No Go

9 Neuropsychological Testing Definitive for diagnosis, but expensive ($2000 $3000) Useful when diagnosis is uncertain (bipolar vs. ADD) Useful when comorbid learning issues may be present (dyslexia) Accommodations for standardized tests Behavioral strategies Pharmacological strategies Therapy Behavioral Strategies in ADHD 1. Children Effective therapies include Teaching children how to communicate emotions Promote positive parent child interaction skills Practicing behavioral modification techniques (rewarding positive behaviors) Behavioral classroom management Positive reinforcement drives behavior, negative reinforcement doesn t work Feldman and Reiff NEJM 2014 Behavioral Strategies in ADHD 2. Adults Impose organizational tools PDAs/ A single organizer/calendar A single To Do list Limit distractions Do only one task at a time, donʼt switch Limit outside noise Consider a personal coach

10 Behavioral Strategies and School Consider neuropsychological testing to confirm diagnosis and determine whether untimed tests, testing in quiet environment, and other accommodations are indicated Behavioral strategies Pharmacological strategies Therapy Pharmacotherapy of ADHD Stimulant Medications Ritalin (methylphenidate) Adderall (mixed salt of dextroamphetamine) Activating antidepressants (Not SSRIs) Tricyclic antidepressants Wellbutrin (bupropion) Other agents Strattera (atomoxetine) norepinephrine reuptake inhibitor Provigil (modafanil) wake promoting agent Stimulant Medications Between 50 80% of subjects will have a good response Relatively contraindicated in people with substance abuse history, especially if abuse is an active issue Illicit use of these drugs is growing, particularly in schools and colleges

11 Side effects of Stimulant Medications Cardiovascular side effects with average of 3 5mm increase in BP, and slight increase in heart rate (5 BPM) otwo retrospective studies looked for cardiac events oone with 150,000 treated with amph, met or atom found no association osecond with 44,000 treated with met vs. nonusers found 1.8 fold increase in sudden death but no dose response and may not be causal Side effects of Stimulant Medications II Anorexia Insomnia Potential for abuse (but also potential to prevent substance abuse) Stimulants Non Stimulants Farone and Glatt J Clin Psych 2010 Farone and Glatt J Clin Psych 2010

12 Overall Efficacy of Stimulant and Non stimulant Medications Short Acting Stimulants 0.96 Cohen D effect size Long Acting Stimulants 0.73 Non Stimulants 0.39 Stimulants > Non Stimulants No significant difference between short and long acting No significant difference between methylphenidate and dextroamphetamine Farone and Glatt J Clin Psych 2010 Drug: Short-acting racemic mixture Intermediate duration Long duration Stereoisomer/ prodrug Methylphenidate Ritalin, methylin (3-4 hrs) 5-10mg bid Ritalin SR (4-7 hrs) 20mg qam (to bid) Concerta, Ritalin LA, Metadate CD, Daytrana patch (8-12 hr) 30-60mg qam Focalin (dmethylphenidate) and Focalin XR (50% dose) Dextroamphetamine Dexedrine (4-5 hrs) 5mg bid Adderall (mixed salt, 4-7 hrs) 10-20mg qam-bid Adderall XR (8-10 hrs) 20-40mg qam Prodrug:Vyvanse 30mg qam Atomoxetine (Strattera) Norepinephrine reuptake inhibitor, somewhat similar to venlafaxine Not habit forming particularly useful in patients with substance abuse concern Has antidepressant properties May not be as effective as stimulants Women of Childbearing Years Should be discussed regularly Goal is to have a plan ahead of time as to whether medication can be tapered Risks are present but low, along with risk of coming off medication if attention symptoms are severe

13 Controversies: Cosmetic Neurology Some are using these medications even in absence of identified disorder Ethics are murky Stimulant use on college campuses as study aid Talk with patients to minimize risk Executive Function poor ideal Executive Function Paradigm Normal function inhibition Set-shifting On task Creativity low intermediate high Dopamine Levels Executive function and Attention clinic 52 New patients Neurological disease? NO Comorbidities? NO NEUROPSYCH TESTING YES (15%) YES (25%) MRI Toxic/Metabolic/Infection EEG LP Psychiatry/ Sleep Resources ADHD in children and adolescents Feldman and Reiff NEJM 2014 ADHD in Adults Volkow and Swanson NEJM 2013 Vanderbilt Assessment Scales for parents and teachers Adult ADHD Self report scale (ASRS) 5_Guidelines.pdf Brainfit club training Prescription medication?tms/tdcs

14 Conclusions ADHD in children and adults is controversial, but the cardinal symptoms are amenable to therapy Differential diagnosis includes medical (OSA) and psychiatric conditions (BPD) Hallmark of therapy is stimulant medication, but behavioral therapies are also effective, particularly in conjunction with medications Precautions need to be exercised in at risk individuals, where newer agents may be safer ASK QUESTIONS USING OUR NEW SOCIAL Q&A FEATURE! Navigate to Click a Session Ask a Question Up-Vote a Question

The Use of ADHD Medication in the Pediatric Population

The Use of ADHD Medication in the Pediatric Population The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications

More information

Attention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD

Attention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD Attention Deficit Hyperactivity Disorder State of the Art Christopher Okiishi, MD What is ADHD? Three subtypes: Inattentive (under diagnosed, esp. in girls) Hyperactive Impulsive Combined Impairments must

More information

Attention Deficit Hyperactivity Disorder A Neuro-Anatomical Approach to diagnosis and treatment

Attention Deficit Hyperactivity Disorder A Neuro-Anatomical Approach to diagnosis and treatment Attention Deficit Hyperactivity Disorder A Neuro-Anatomical Approach to diagnosis and treatment Damon Lipinski, Ph.D. Clinical Psychologist Center for Pediatric Neuropsychology What is Attention? Different

More information

AD/HD is a mental disorder, and it often lasts from

AD/HD is a mental disorder, and it often lasts from short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.

More information

Psychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.

Psychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved. Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence

More information

Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor

Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry

More information

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6 in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,

More information

ADHD Part II: Managing Comorbities

ADHD Part II: Managing Comorbities ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have

More information

Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D.

Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. PREVALENCE & STATISTICS 6-8% of all children have ADHD (CDC Statistical Data) Age of onset: 7 years old (Prior DSM-IV) 12 years old (Current

More information

Perspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry

Perspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator

More information

Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition

Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition Presented by Cat Dang, D.O Medical Director - Insightful Minds, Inc. Objectives Evaluation process Pharmacology

More information

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD

More information

Pediatric Psychopharmacology

Pediatric Psychopharmacology Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders

More information

ADHD: A Focus On Drug Therapy

ADHD: A Focus On Drug Therapy ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90

More information

What are the most common signs of ADHD? And what are the most common medication interventions?

What are the most common signs of ADHD? And what are the most common medication interventions? What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina

More information

Week 2: Disorders of Childhood

Week 2: Disorders of Childhood Week 2: Disorders of Childhood What are neurodevelopmental disorders? A group of conditions with onset in the developmental period Disorders of the brain The disorders manifest early in development, often

More information

ADHD Medications & How They Work. Gail C. Rodin, Ph.D. January 21, 2008

ADHD Medications & How They Work. Gail C. Rodin, Ph.D. January 21, 2008 ADHD Medications & How They Work Gail C. Rodin, Ph.D. January 21, 2008 Agenda How the (ADHD) Brain Works (or doesn t) Neurons and neurotransmitters NE & DA: the major players in ADHD Channel vs. state

More information

Practical Psychopharmacology for More Complex Mental Health Presentations

Practical Psychopharmacology for More Complex Mental Health Presentations MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More

More information

Psychiatric Medications. Positive and negative effects in the classroom

Psychiatric Medications. Positive and negative effects in the classroom Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children

More information

ADHD Medications Table

ADHD Medications Table Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common

More information

Ask The Shrink: ADHD

Ask The Shrink: ADHD Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'

More information

Dose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.

Dose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs. MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)

More information

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand The 25th Federation Of Asian Pharmaceutical Association (FAPA) Congress 2014 Kota Kinabalu, Sabah, Malaysia 9th - 12th October, 2014 Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit

More information

Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The

More information

Contents Definition and History of ADHD Causative Factors

Contents Definition and History of ADHD Causative Factors 1 Definition and History of ADHD................... 1 Brain Damage Syndromes........................ 1 Alternative Terms for ADHD...................... 2 Evolution of Present Concept of ADHD................

More information

Pharmacologic Management of ADHD

Pharmacologic Management of ADHD Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy

Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy Questions from chapter 1 1) For a diagnosis of ADHD, some symptoms that cause impairment must be present before

More information

6/2/2011. At the end of the presentation you will be able to: What is Adult Attention Deficit Hyperactivity Disorder?

6/2/2011. At the end of the presentation you will be able to: What is Adult Attention Deficit Hyperactivity Disorder? At the end of the presentation you will be able to: Adult Attention Deficit Hyperactive Disorder (ADHD) Concern for our patients wellbeing. 1. Describe the most common behaviors and problems associated

More information

ADHD Medications: Basics. David Benhayon MD, PhD

ADHD Medications: Basics. David Benhayon MD, PhD ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in

More information

Attention Deficit Hyperactivity Disorder Overview and New Perspectives

Attention Deficit Hyperactivity Disorder Overview and New Perspectives 1st Annual Regional Psychiatry Conference Psychiatry for the Non-Psychiatrist Attention Deficit Hyperactivity Disorder Overview and New Perspectives Thomas B. Henry, MD Board Certified Child & Adolescent

More information

We ll Be Discussing. Pregnancy 4/24/2013

We ll Be Discussing. Pregnancy 4/24/2013 Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free monthly e-newsletter? We ll Be Discussing The safety and efficacy track

More information

Pharmacotherapy of ADHD Across the Lifecycle: Stimulants

Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Percent Change (Bmax/Kd) DVR Images Obtained with [ 11 C]Raclopride

More information

2013 Virtual AD/HD Conference 1

2013 Virtual AD/HD Conference 1 Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com

More information

Treating Disruptive Behavior Disorders in Children and Teens. A Review of the Research for Parents and Caregivers

Treating Disruptive Behavior Disorders in Children and Teens. A Review of the Research for Parents and Caregivers Treating Disruptive Behavior Disorders in Children and Teens A Review of the Research for Parents and Caregivers e Is This Information Right for Me? This information is for you if: A health care professional*

More information

Presented by the National Resource Center on ADHD

Presented by the National Resource Center on ADHD Presented by the National Resource Center on ADHD Timothy E. Wilens, M.D. Massachusetts General Hospital Harvard Medical School Save 25% if you join/rejoin CHADD Use Promo Code: JANA14 If you are currently

More information

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

PL CE LIVE February 2011 Forum

PL CE LIVE February 2011 Forum February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics

More information

A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE

A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE OVERVIEW Review Stimulant Treatment for ADHD STIMULANTS

More information

Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants

Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Pharmacotherapy of Adult ADHD

Pharmacotherapy of Adult ADHD Pharmacotherapy of Adult ADHD Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Disclosures Dr. Spencer receives research support from Royalties and Licensing fees on copyrighted

More information

7/9/2013. Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly. What ADHD is

7/9/2013. Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly. What ADHD is Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly Gabrielle A. Carlson, MD Professor of Psychiatry and Pediatrics Director, Child and Adolescent Psychiatry Stony

More information

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

475 Child & Adolescent Psychopharmacology p.1

475 Child & Adolescent Psychopharmacology p.1 475 Child & Adolescent Psychopharmacology p.1 Introduction? #s of prescriptions for psychoactive meds have increased x2-3 in last 10 years? Ability to diagnose psychiatric disorders in children/adolescents

More information

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative

More information

Evaluation and Treatment of AD/HD in the Primary Pediatric

Evaluation and Treatment of AD/HD in the Primary Pediatric Evaluation and Treatment of AD/HD in the Primary Pediatric Clinic Carolyn Lentzsch-Parcells, MD Assistant Professor University of Kentucky, Department of Pediatrics April 9, 2009 GOALS The learners will

More information

Child & Adolescent Psychiatry (a brief overview)

Child & Adolescent Psychiatry (a brief overview) Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina

More information

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine

More information

Evidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center

Evidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to

More information

The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications

The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications Society for the Study of Addiction, York The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications November 12.th 2010 Soren Dalsgaard, MD, PhD, associate

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Conversion from focalin xr to vyvanse

Conversion from focalin xr to vyvanse Conversion from focalin xr to vyvanse The Borg System is 100 % Conversion from focalin xr to vyvanse Sep 3, 2007. The importance of the 'conversion' dosing listed above relates to those people who may

More information

Update on the Treatment of ADHD 2019

Update on the Treatment of ADHD 2019 Update on the Treatment of ADHD 2019 James H. Beard, Jr., M.D, FAAP Developmental-Behavioral Pediatrician Division of Developmental Pediatrics The Rights of ADHD The right diagnosis of ADHD and co morbidities

More information

DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES

DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES Scott R. Smith, MD, MPH Developmental-Behavioral Pediatrician University of Rochester Medical Center Common Complaints about Children with Problems Your

More information

Differential Diagnosis of Complex Adult Patients with ADHD. Dr. Taher Shaltout Senior Consultant, Psychiatrist Hamad Medical Corporation

Differential Diagnosis of Complex Adult Patients with ADHD. Dr. Taher Shaltout Senior Consultant, Psychiatrist Hamad Medical Corporation Differential Diagnosis of Complex Adult Patients with ADHD Dr. Taher Shaltout Senior Consultant, Psychiatrist Hamad Medical Corporation What is ADHD? How do you diagnose it in adults? How do you treat

More information

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)

More information

Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines

Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines Umesh Jain B.Sc., M.D., F.R.C.P.(C), D.A.B.P.N., Ph.D., M.Ed. (Cand.) Hospital for Sick Children /Centre for Addiction and

More information

About ADHD. National Resource Center on ADHD A Program of CHADD

About ADHD. National Resource Center on ADHD A Program of CHADD About ADHD Everybody can have difficulty sitting still, paying attention or controlling impulsive behavior once in a while. For some people, however, the problems are so pervasive and persistent that they

More information

Focalin compared to concerta

Focalin compared to concerta Focalin compared to concerta Search FREE SHIPPING how does focalin compared to concerta. Free shipping, quality, privacy, secure. how does focalin compared to concerta. Compare Ritalin vs. Focalin. Focalin

More information

Psychiatric medication treatment in children and adolescents:

Psychiatric medication treatment in children and adolescents: Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly Gabrielle A. Carlson, MD Professor of Psychiatry and Pediatrics Director, Child and Adolescent Psychiatry Stony

More information

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.

More information

Recognition and Treatment of ADHD in Primary Care Settings. Disclosure 11/6/2013. Objectives

Recognition and Treatment of ADHD in Primary Care Settings. Disclosure 11/6/2013. Objectives Southern California Permanente Medical Group Pediatric Symposium Hyatt, Long Beach CA. 11/1/13 Recognition and Treatment of ADHD in Primary Care Settings Martin T. Stein, M.D. Professor of Pediatrics Division

More information

Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities

Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities By: Dr. Ehsane M. Gad M.B.B.Ch CABMSPsych. D.P.P Post-Fellow Aus. Consultant Child Psychiatry Childhood ADHD and emergence

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Individuals with attention-deficit/hyperactivity

Individuals with attention-deficit/hyperactivity 3 W H A T W E K N O W Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience chronic problems with inattention and/or

More information

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);

More information

Adult ADHD. 1. Overview of ADHD 4. Principles for managing ADHD. 2. Common features of ADHD in adults. 3. General approaches to managing ADHD

Adult ADHD. 1. Overview of ADHD 4. Principles for managing ADHD. 2. Common features of ADHD in adults. 3. General approaches to managing ADHD Adult ADHD 1. Overview of ADHD 4. Principles for managing ADHD 2. Common features of ADHD in adults 3. General approaches to managing ADHD Definition The name... 1. Overview of ADHD Definition Attention

More information

The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD

The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD Damon Korb, MD Behavioral and Developmental Pediatrician Director of the Center for Developing Minds Los Gatos,

More information

ADHD: A Life Script from Conception to Adulthood

ADHD: A Life Script from Conception to Adulthood Page 1 Attention Deficit Hyperactivity Disorder A Life Script from Conception to Adulthood A life script from conception to adulthood. Elizabeth A. Montagnese, M.D. Child and Adult Psychiatrist Speaker:

More information

Child/Adolescent Attention-Deficit/Hyperactivity Disorder

Child/Adolescent Attention-Deficit/Hyperactivity Disorder Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 2009 National Child/Adolescent Attention-Defict/ Hyperactivity

More information

ADHD: Management Update

ADHD: Management Update 4/5/17 Conflicts of Interest ADHD: Management Update I have no conflicts to disclose. Jennifer R. Walton, MD, MPH, FAAP April 7, 2017 ADHD: DSM-5 Definition Objectives To briefly review ADHD diagnostic

More information

Brief Notes on the Mental Health of Children and Adolescents

Brief Notes on the Mental Health of Children and Adolescents Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

ADHD DIAGNOSIS AND MANAGEMENT

ADHD DIAGNOSIS AND MANAGEMENT ADHD DIAGNOSIS AND MANAGEMENT Cesar Ochoa, MD Head, Developmental-Behavioral Pediatrics Rush University Medical Center Medical Director, Rush Neurobehavioral Center April 28,2017 LEARNING OBJECTIVES 1.

More information

ADHD DIAGNOSIS AND MANAGEMENT LEARNING OBJECTIVES CASE 4/28/2017

ADHD DIAGNOSIS AND MANAGEMENT LEARNING OBJECTIVES CASE 4/28/2017 ADHD DIAGNOSIS AND MANAGEMENT Cesar Ochoa, MD Head, Developmental-Behavioral Pediatrics Rush University Medical Center Medical Director, Rush Neurobehavioral Center April 28,2017 LEARNING OBJECTIVES 1.

More information

Child/Adolescent Attention-Deficit/Hyperactivity Disorder

Child/Adolescent Attention-Deficit/Hyperactivity Disorder Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity

More information

NASET Q & A Corner Issue #21 Questions and Answers About

NASET Q & A Corner Issue #21 Questions and Answers About NASET Q & A Corner Issue #21 Questions and Answers About Attention Deficit Hyperactivity Disorder (ADHD) What is attention deficit hyperactivity disorder? Attention deficit hyperactivity disorder (ADHD)

More information

Individuals with attention-deficit/hyperactivity

Individuals with attention-deficit/hyperactivity National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience

More information

ADHD in the Preschool Aged Child

ADHD in the Preschool Aged Child ADHD in the Preschool Aged Child (PATS) 11/2/2013 Stephen Meister MD, MHA, FAAP The Edmund N Ervin Pediatric Center (PATS) National Institute of Mental Health study First papers published in 2006 after

More information

ATTENTION DEFICIT HYPERACTIVITY DISORDER COMORBIDITIES 23/02/2011. Oppositional Defiant Disorder

ATTENTION DEFICIT HYPERACTIVITY DISORDER COMORBIDITIES 23/02/2011. Oppositional Defiant Disorder ATTENTION DEFICIT HYPERACTIVITY DISORDER COMORBIDITIES The comorbidity of ADHD with other disorders is between 60% and 80% The most commonly comorbid disorder that occur alongside ADHD are: Oppositional

More information

Effectively Recognizing and Managing ADHD in Adolescents. Educational Objectives

Effectively Recognizing and Managing ADHD in Adolescents. Educational Objectives Educational Objectives After completing this activity, the participant should be better able to: Explain how the proper recognition and management of ADHD in adolescents by MCOs can improve clinical outcomes

More information

QUANTITY LIMIT CRITERIA

QUANTITY LIMIT CRITERIA DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS

More information

TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD)

TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD) TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD) TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) The clinical tool kit is intended

More information

Individuals with attention-deficit/hyperactivity

Individuals with attention-deficit/hyperactivity National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience

More information

ADHD & INTELLECTUAL DISABILTIY

ADHD & INTELLECTUAL DISABILTIY ADHD & INTELLECTUAL DISABILTIY HOME STUDY, 1 HOUR ATTENTION DEFICIT HYPERACTIVITY DISORDER ADD Attention Deficit Disorder ADHD Attention Deficit - Hyperactivity Disorder According to the DSM-5, ADHD is

More information

Parents Guide to ADHD Medications. Copyright Child Mind Institute

Parents Guide to ADHD Medications. Copyright Child Mind Institute Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive

More information

ADHD: Beyond the DSM Emotion in ADHD

ADHD: Beyond the DSM Emotion in ADHD ADHD: Beyond the DSM ADHD is a common condition: Old data: 3 5% of school age population True incidence 8 10% of population, not just school age Affect millions of American families Impacts almost every

More information

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:

More information

Differentiating Unipolar vs Bipolar Depression in Children

Differentiating Unipolar vs Bipolar Depression in Children Differentiating Unipolar vs Bipolar Depression in Children Mai Uchida, M.D. Director, Center for Early Identification and Prevention of Pediatric Depression Massachusetts General Hospital Assistant Professor

More information

2013 Virtual AD/HD Conference 1

2013 Virtual AD/HD Conference 1 Medication for ADHD & Coexisting Conditions Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com www.adhdpodcast.com

More information

IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING

IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING FOR IMMEDIATE RELEASE IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING George Town, Cayman Islands January 10, 2019 Ironshore

More information

Update on NIMH Study & ADHD Medications. NIMH MTA Study. Implications of the. NIMH MTA ADHD Study. NIMH ADHD MTA Study.

Update on NIMH Study & ADHD Medications. NIMH MTA Study. Implications of the. NIMH MTA ADHD Study. NIMH ADHD MTA Study. Update on NIMH Study & ADHD Medications ADHD Conference Riyadh, Saudi Arabia October 29, 2008 Implications of the NIMH MTA Study Chris A. Zeigler Dendy & Dr. Billie Abney www.chrisdendy.com chris@chrisdendy.com

More information

CE on SUNDAY Melville, NY September 20, 2009

CE on SUNDAY Melville, NY September 20, 2009 CE on SUNDAY Melville, NY September 20, 2009 Date: Sunday, September 20, 2009 Time: 8:00 AM 9:00 AM Location: Melville Marriott Long Island Title: Speaker(s): ADHD: A Life Script from Conception to Adulthood

More information

EDUCATORS TOOLKIT FOR DEALING WITH ADHD IN THE CLASSROOM

EDUCATORS TOOLKIT FOR DEALING WITH ADHD IN THE CLASSROOM EDUCATORS TOOLKIT FOR DEALING WITH ADHD IN THE CLASSROOM Linda Miller-Dunleavy Old Dominion University Communication Disorders & Special Education lmillerd@odu.edu UNDERSTANDING STUDENTS WITH ATTENTION-DEFICIT

More information

AD/HD Across the Lifespan. Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida.

AD/HD Across the Lifespan. Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida. AD/HD Across the Lifespan Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida. Worldwide Prevalence of ADHD Is 3% to 7% Studies of ADHD prevalence United

More information

MANAGEMENT OF ADHD IN ADULTS

MANAGEMENT OF ADHD IN ADULTS MANAGEMENT OF ADHD IN ADULTS RICHARD MOLDAWSKY, M.D. I Can t Focus on Anything Except Getting My Adderall 1 ASSUMPTIONS FOR TODAY Most of us don t work 2 W s without seeing a person with ADHD You are familiar

More information

The Adolescent with ADHD: Managing Transition

The Adolescent with ADHD: Managing Transition The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli

More information

The use of neurofeedback as a clinical intervention for refugee children and adolescents FASSTT conference 2017

The use of neurofeedback as a clinical intervention for refugee children and adolescents FASSTT conference 2017 The use of neurofeedback as a clinical intervention for refugee children and adolescents FASSTT conference 2017 FASSTT 2017 Paper presentation Trix Harvey, NFB/Biofeedback clinic team leader at STARTTSS

More information

MRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist

MRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:

More information